Our first product was approved and made available to NHS hospitals in May 2019, our second product was made available to NHS and private hospitals in March 2020. Our portfolio will increase in 2021.

We are proud to have an exceptional partner in Phebra Pty Ltd who have their own modern MHRA and FDA approved specialist injectable medicines manufacturing facility which has ample capacity to supply UK demand. In addition, because of the mutual recognition agreements in place between the regulatory authorities of the UK and Australia supply of finished product into the UK from Australia, is straightforward and fast.

Arsenic Trioxide Phebra 1mg/ml concentrate solution for infusion

Indicated for the treatment of low-intermediate risk acute promyelocytic leukaemia, this is a novel presentation of arsenic trioxide. The Summary of Product Characteristics can be found at https://www.medicines.org.uk/ emc/product/10278/smpc

Arsenic Trioxide Phebra is a generic product which offers several advantages to the NHS;

  1. Saves money. Arsenic Trioxide Phebra has an NHS/list price 7.7% less than equivalent arsenic trioxide ampoules; a pack of Arsenic Trioxide Phebra has an NHS price £220 less than the ampoule product1
  2. Saves time. Because it is a vial there is no need to use a filter needle/straw to draw up drug, this reduces the number of steps and time needed to make an infusion compared to using an ampoule
  3. Reduce risks. Vials are not associated with sharps injuries which are common from jagged edges or glass splinters from opening ampoules. A clear plastic sleeve and base cup, unique to our Arsenic Trioxide product also act to protect NHS staff from exposure to contents should the vial be broken

Further information can be found at www.arsenictrioxidephebra.com

References
1. https://bnf.nice.org.uk/medicinal-forms/arsenic-trioxide.html

Methylthioninium Chloride 10mg/ml sterile concentrate for solution for injection

Indicated primarily in the treatment of medicinal and chemical induced and genetic methaemoglobinaemia that are not due to a structural abnormality ofhaemoglobin. Methylthiononinium Chloride is indicated in adults, adolescentsand children (0-17 years old.) The summary of product characteristics can be found at https://www.medicines.org.uk/emc/product/11181

Flexipharm Austrading’s Methylthioninium Chloride 10mg/ml Sterile concentrate for solution for injection is the first and only generic licensed medicinal product presentation of methylthioninium chloride to be available in a preferred vial presentation. As an MHRA licensed and European Pharmacopoeia compliant product, it meets or exceeds specifications on levels of organic and metal impurities, and has several benefits to the NHS, notably:

  1. Lower cost and fewer steps to prepare the drug for administration compared to the alternative ampoule product
  2. Removal of ‘sharps’ injury risk, often associated with opening ampoules
  3. An NHS/List price which is £46.89 per pack or 23% cheaper than the alternative ampoule product1
  4. Improved shelf life – can be used for up to 24 hours from opening, compared to the alternative ampoule product which must be used immediately

References
1. https://bnf.nice.org.uk/medicinal-forms/methylthioninium-chloride.html, ampoules, £196.89 per pack, accessed 04/03/2020. NHS/List price Methylthioninium Chloride vials £150.00 per pack

© Flexipharm Austrading Ltd 2019
Privacy Policy
Cookies Policy